Skip to content

Chloé Pronovost-Morgan

3 papers in the library · 61 citations · publishing 2023-2025

Papers

Sort Most recent Most cited

An international Delphi consensus for reporting of setting in psychedelic clinical trials.

Nature Medicine June 3, 2025 Chloé Pronovost-Morgan, Kyle T. Greenway, Leor Roseman et al. 26 citations

Psychedelic substances exhibit complex interactions with the 'set and setting' of use, that is, the mental state of the user and the environment in which a psychedelic experience takes place. Despite these contextual variables' known importance, psychedelic research has lacked methodological rigor in reporting extra-pharmacological factors. This study aimed to generate consensus-based...

The Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) Guidelines: An international Delphi consensus study

Research Square November 18, 2024 Chloé Pronovost-Morgan, Kyle T. Greenway, Leor Roseman 2 citations

Abstract Background Psychedelic substances exhibit complex interactions with the ‘set and setting’ of use, i.e., the internal state of the user and the external environment in which a psychedelic experience takes place. Despite the known importance of these contextual variables, psychedelic research has suffered from methodological weaknesses in reporting extra-pharmacological factors and from...

Harnessing placebo: Lessons from psychedelic science.

J Psychopharmacol June 30, 2023 Chloé Pronovost-Morgan, Ido Hartogsohn, Johannes G. Ramaekers 33 citations

The randomized controlled trial (RCT) research design assumes that a drug's "specific" effect can be isolated, added, and subtracted from the "nonspecific" effect of context and person. While RCTs are helpful in assessing the added benefit of a novel drug, they tend to obscure the curative potential of extra-pharmacological variables, known as "the placebo effect." Ample empirical evidence...